Abstract
Objective To analyse the clinical efficacy of treatment of the neovascular glaucoma with different intraocular pressure. Methods A total of 111 eyes of 100 patients with neovascular glaucoma from September 2013 to December 2015 were enrolled .They according to the IOP before treatment were divided into four groups: Group A, 18-21 mmHg (1 mmHg=0.133 kPa) in 20 eyes of 19 cases; Group B, 22-30 mmHg in 30 eyes of 28 cases; Group C, 31-40 mmHg in 31 eyes of 28 cases; Group D, ≥41mmHg in 30 eyes of 25 cases .Group A and Group B received the panretinal photocoagulation, Group C received intravitreal ranibizumab injection firstly , then received the panretinal photocoagulation, Group D received intravitreal injection of ranibizumab firstly , then received the trabeculectomy combined with panretinal photocoagulation . At 1 week, 1 month and 3 months after treatment the intraocular pressure, corneal edema degree, iris neovascularization subsided and complications were observed. Results After treatment new vessels subsided in Group A was 17 eyes , Group B in 24 eyes, Group C in 26 eyes, and Group D in 22 eyes .In Group A, the difference in IOP between before and after treatment was not significant (P=0.342, 0.101, 0.591), the difference in IOP after treatment in other groups compared with before treatment was statistically significant (P=0.000). Conclusion Different treatments are used to treat patients with neovascular glaucoma with different intraocular pressure. Key words: Glaucoma, neovascular; Intraocular pressure; Ranibizumab; Trabeculectomy; Photocoagulation, panretinal
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.